Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $17.25

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $17.25.

Several analysts have issued reports on ENTA shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $4.64 on Friday. Enanta Pharmaceuticals has a 52 week low of $4.23 and a 52 week high of $17.24. The company’s 50 day moving average price is $6.38 and its two-hundred day moving average price is $7.90. The company has a market capitalization of $98.99 million, a P/E ratio of -0.94 and a beta of 0.69.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Analysts forecast that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Activity

In related news, CEO Jay R. Luly acquired 45,000 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.89% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after acquiring an additional 85,082 shares during the period. Assenagon Asset Management S.A. lifted its stake in Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after purchasing an additional 49,050 shares during the last quarter. Barclays PLC lifted its stake in Enanta Pharmaceuticals by 294.2% in the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 20,478 shares during the last quarter. Geode Capital Management LLC grew its holdings in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 14,575 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Enanta Pharmaceuticals during the third quarter worth approximately $903,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.